Source: Pharmacy Times articles
The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.
Read More
by | Sep 17, 2024 | Myeloma News | 0 comments
Source: Pharmacy Times articles
The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.
Read More